Table 1.
Open in new tab

In vitro activity of daptomycin against select Gram-positive bacteria

OrganismNo. of strainsMIC range (mg/L)MIC90 (mg/L)Reference
Select aerobic pathogens
    Staphylococcus aureus
        oxacillin-resistant
         European isolates3340.12–10.514
         worldwide isolates1247 ≤ 0.12–10.521
        oxacillin-susceptible
         European isolates888 ≤ 0.015–10.514
         worldwide isolates1955 ≤ 0.12–20.521
    Coagulase-negative staphylococcia
        European isolates10400.03–10.514
        worldwide isolates838 ≤ 0.12–20.521
    β-Haemolytic streptococci
        European isolatesb3670.06–10.2514
        worldwide isolates247 ≤ 0.12–0.50.2521
    Enterococcus faecalis
        vancomycin-susceptible
         European isolates1789 ≤ 0.015–4214
         worldwide isolates626 ≤ 0.12–4121
        vancomycin-resistant
         European isolates40 ≤ 0.5–4214
         worldwide isolates200.25–1121
    Enterococcus faecium
        vancomycin-susceptible
         European isolates3330.03–8414
         worldwide isolates97 ≤ 0.12–8421
        vancomycin-resistant
         European isolates1140.25–4414
         worldwide isolates550.25–4421
    Enterococcus spp.c
        European isolates160 ≤ 0.015–4414
        worldwide isolates210.5–4221
    Corynebacterium jeikeium100.125–0.50.2528
Select anaerobic pathogens
    Actinomyces group220.06–16.0428
    Bifidobacterium spp.13 < 0.03–1.00.528
    Clostridium difficile180.125–1.0128
    Clostridium perfringens110.06–0.50.528
    Lactobacillus spp.d37 < 0.03–32.01628
    Peptostreptococcus spp.140.125–1128
    Propionibacterium spp.150.125–2228
OrganismNo. of strainsMIC range (mg/L)MIC90 (mg/L)Reference
Select aerobic pathogens
    Staphylococcus aureus
        oxacillin-resistant
         European isolates3340.12–10.514
         worldwide isolates1247 ≤ 0.12–10.521
        oxacillin-susceptible
         European isolates888 ≤ 0.015–10.514
         worldwide isolates1955 ≤ 0.12–20.521
    Coagulase-negative staphylococcia
        European isolates10400.03–10.514
        worldwide isolates838 ≤ 0.12–20.521
    β-Haemolytic streptococci
        European isolatesb3670.06–10.2514
        worldwide isolates247 ≤ 0.12–0.50.2521
    Enterococcus faecalis
        vancomycin-susceptible
         European isolates1789 ≤ 0.015–4214
         worldwide isolates626 ≤ 0.12–4121
        vancomycin-resistant
         European isolates40 ≤ 0.5–4214
         worldwide isolates200.25–1121
    Enterococcus faecium
        vancomycin-susceptible
         European isolates3330.03–8414
         worldwide isolates97 ≤ 0.12–8421
        vancomycin-resistant
         European isolates1140.25–4414
         worldwide isolates550.25–4421
    Enterococcus spp.c
        European isolates160 ≤ 0.015–4414
        worldwide isolates210.5–4221
    Corynebacterium jeikeium100.125–0.50.2528
Select anaerobic pathogens
    Actinomyces group220.06–16.0428
    Bifidobacterium spp.13 < 0.03–1.00.528
    Clostridium difficile180.125–1.0128
    Clostridium perfringens110.06–0.50.528
    Lactobacillus spp.d37 < 0.03–32.01628
    Peptostreptococcus spp.140.125–1128
    Propionibacterium spp.150.125–2228
a

Includes methicillin-resistant isolates vancomycin-resistant isolates.

b

European isolates were S. agalactiae only.

c

Includes vancomycin-resistant isolates.

d

All Lactobacillus spp. were grown anaerobically.

Table 1.
Open in new tab

In vitro activity of daptomycin against select Gram-positive bacteria

OrganismNo. of strainsMIC range (mg/L)MIC90 (mg/L)Reference
Select aerobic pathogens
    Staphylococcus aureus
        oxacillin-resistant
         European isolates3340.12–10.514
         worldwide isolates1247 ≤ 0.12–10.521
        oxacillin-susceptible
         European isolates888 ≤ 0.015–10.514
         worldwide isolates1955 ≤ 0.12–20.521
    Coagulase-negative staphylococcia
        European isolates10400.03–10.514
        worldwide isolates838 ≤ 0.12–20.521
    β-Haemolytic streptococci
        European isolatesb3670.06–10.2514
        worldwide isolates247 ≤ 0.12–0.50.2521
    Enterococcus faecalis
        vancomycin-susceptible
         European isolates1789 ≤ 0.015–4214
         worldwide isolates626 ≤ 0.12–4121
        vancomycin-resistant
         European isolates40 ≤ 0.5–4214
         worldwide isolates200.25–1121
    Enterococcus faecium
        vancomycin-susceptible
         European isolates3330.03–8414
         worldwide isolates97 ≤ 0.12–8421
        vancomycin-resistant
         European isolates1140.25–4414
         worldwide isolates550.25–4421
    Enterococcus spp.c
        European isolates160 ≤ 0.015–4414
        worldwide isolates210.5–4221
    Corynebacterium jeikeium100.125–0.50.2528
Select anaerobic pathogens
    Actinomyces group220.06–16.0428
    Bifidobacterium spp.13 < 0.03–1.00.528
    Clostridium difficile180.125–1.0128
    Clostridium perfringens110.06–0.50.528
    Lactobacillus spp.d37 < 0.03–32.01628
    Peptostreptococcus spp.140.125–1128
    Propionibacterium spp.150.125–2228
OrganismNo. of strainsMIC range (mg/L)MIC90 (mg/L)Reference
Select aerobic pathogens
    Staphylococcus aureus
        oxacillin-resistant
         European isolates3340.12–10.514
         worldwide isolates1247 ≤ 0.12–10.521
        oxacillin-susceptible
         European isolates888 ≤ 0.015–10.514
         worldwide isolates1955 ≤ 0.12–20.521
    Coagulase-negative staphylococcia
        European isolates10400.03–10.514
        worldwide isolates838 ≤ 0.12–20.521
    β-Haemolytic streptococci
        European isolatesb3670.06–10.2514
        worldwide isolates247 ≤ 0.12–0.50.2521
    Enterococcus faecalis
        vancomycin-susceptible
         European isolates1789 ≤ 0.015–4214
         worldwide isolates626 ≤ 0.12–4121
        vancomycin-resistant
         European isolates40 ≤ 0.5–4214
         worldwide isolates200.25–1121
    Enterococcus faecium
        vancomycin-susceptible
         European isolates3330.03–8414
         worldwide isolates97 ≤ 0.12–8421
        vancomycin-resistant
         European isolates1140.25–4414
         worldwide isolates550.25–4421
    Enterococcus spp.c
        European isolates160 ≤ 0.015–4414
        worldwide isolates210.5–4221
    Corynebacterium jeikeium100.125–0.50.2528
Select anaerobic pathogens
    Actinomyces group220.06–16.0428
    Bifidobacterium spp.13 < 0.03–1.00.528
    Clostridium difficile180.125–1.0128
    Clostridium perfringens110.06–0.50.528
    Lactobacillus spp.d37 < 0.03–32.01628
    Peptostreptococcus spp.140.125–1128
    Propionibacterium spp.150.125–2228
a

Includes methicillin-resistant isolates vancomycin-resistant isolates.

b

European isolates were S. agalactiae only.

c

Includes vancomycin-resistant isolates.

d

All Lactobacillus spp. were grown anaerobically.

Close
This Feature Is Available To Subscribers Only

Sign In or Create an Account

Close

This PDF is available to Subscribers Only

View Article Abstract & Purchase Options

For full access to this pdf, sign in to an existing account, or purchase an annual subscription.

Close